Suvretta Capital Management’s Inozyme Pharma INZY Stock Holding History

Suvretta Capital Management’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,013,216	Closed	-$4.14M	–	94
2022 Q1	$4.14M	Hold	1,013,216	–	–	0.13%	65
2021 Q4	$6.91M	Buy	1,013,216 +26,816	+3%	+$232K	0.13%	67
2021 Q3	$11.4M	Buy	986,400 +621,228	+170%	+$9.69M	0.19%	64
2021 Q2	$6.22M	Buy	365,172 +23,745	+7%	+$413K	0.09%	87
2021 Q1	$6.76M	Buy	341,427 +127,116	+59%	+$2.8M	0.1%	82
2020 Q4	$4.42M	Buy	+214,311	New	+$5.11M	0.06%	81

Other funds holding INZY

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Suvretta Capital Management's INZY Position: Q2 2022 in Review

Suvretta Capital Management sold out of Inozyme Pharma (INZY) in Q2 2022, closing a stake of 1,013,216 shares — an estimated $4.14M sold.

Suvretta Capital Management first reported a position in INZY in Q4 2020 and held it in 6 quarters. The position peaked at $11.4M in Q3 2021. 47 funds tracked by Wall St. Rank hold INZY as of Q2 2022.

Suvretta Capital Management reported no remaining Inozyme Pharma position as of Q2 2022 after selling out during the quarter.
Suvretta Capital Management sold 1,013,216 Inozyme Pharma shares in Q2 2022, an estimated $4.14M.
Suvretta Capital Management first reported a position in Inozyme Pharma in Q4 2020 and held it in 6 quarters.
Suvretta Capital Management's Inozyme Pharma position peaked at $11.4M in Q3 2021.
47 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.